Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

What are all the active Destiny 2 codes? Emblems are essential to authentic Guardian flair. They offer an opportunity for expression among your fireteam, the random Guardians you encounter in the ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

Fire Emblem: The Sacred Stones maybe the eighth game, but many people might remember it as only the first or second one they played. This is because the first worldwide release was Fire Emblem ...

ToolGen, Inc. a global leader in genome editing technology, announced that it has filed a patent infringement lawsuit in the United Kingdom against Vertex Pharmaceuticals and its commercial ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF).

It directed to issue notices through print and visual media to remove all kinds of unauthorised flags, emblems, names, symbols, and logos which are prohibited, and discontinue unauthorised use ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...